Associations - PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)

PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
PTPN11 mutation	Juvenile Myelomonocytic Leukemia	PTPN11 mutation	Juvenile Myelomonocytic Leukemia	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
PTPN11 mutations + MCL1 overexpression	Acute Myelogenous Leukemia	PTPN11 mutations + MCL1 overexpression	Acute Myelogenous Leukemia	RG7388 Sensitive: C3 – Early Trials RG7388 Sensitive : C3	RG7388 Sensitive: C3 – Early Trials RG7388 Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
FLT3 mutation + PTPN11 mutation	Acute Myelogenous Leukemia	FLT3 mutation + PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
FLT3 mutation + NRAS mutation + PTPN11 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NRAS mutation + PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
PTPN11 mutation + TMB-H	Melanoma	PTPN11 mutation + TMB-H	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression	Non Small Cell Lung Cancer	KRAS mutation + PTPN11 overexpression + PD-L1 overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)

Associations(19)

Associations
(19)